| Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study 2004 · group A (soy tablets) · Postmenopausal healthy women with an intact uterus | 150 mg | 5 years | 179 |
| Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer 2008 · Soy protein (SPI+) · Men at high risk of prostate cancer or with HGPIN, ASAP, or low-grade prostate cancer | 107 mg | 26 weeks | — |
| Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer 2008 · Alcohol-washed soy protein (SPI-) · Men at high risk of prostate cancer or with HGPIN, ASAP, or low-grade prostate cancer | 6 mg | 26 weeks | — |
| Associations between urine excretion of isoflavonoids and cognition in postmenopausal women in the Women's Isoflavone Soy Health clinical trial 2014 · daily ISP · healthy postmenopausal women aged 45–92 years | 91 mg | 913 days | 150 |
| Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women 2015 · 80 mg isoflavones · Healthy postmenopausal women aged 45.8–65.0 years, selected for at-risk bone mineral density and without diagnosed chronic disease | 80 mg | 3 years | 77 |
| Soy Isoflavones for Reducing Bone Loss Study: effects of a 3-year trial on hormones, adverse events, and endometrial thickness in postmenopausal women 2015 · 120 mg isoflavones · Healthy postmenopausal women aged 45.8–65.0 years, selected for at-risk bone mineral density and without diagnosed chronic disease | 120 mg | 3 years | 73 |
| [Effect of milk product with soy isoflavones on quality of life and bone metabolism in postmenopausal Spanish women: randomized trial] 2012 · Group S · Postmenopausal Spanish women; age range and health conditions not specified | 50 mg | 1 year | 48 |
| Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial 2022 · soy isoflavones group · Adult women over 18 years and before menopause/perimenopause, diagnosed with migraine | 50 mg | 8 weeks | 44 |
| Benefits of soy isoflavone therapeutic regimen on menopausal symptoms 2002 · isoflavone · postmenopausal women | 100 mg | 120 days | 40 |
| Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study 2006 · isoflavone · Postmenopausal women | 120 mg | 26 weeks | 40 |
| Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study 2007 · soy isoflavone group · postmenopausal women with at least 5 hot flush episodes per day; mean age 55.1 years | 100 mg | 300 days | 40 |
| Consumption of a soy drink has no effect on cognitive function but may alleviate vasomotor symptoms in post-menopausal women; a randomised trial 2020 · Low-dose group · Apparently healthy post-menopausal women, within 1–7 years since their last menstrual period | 10 mg | 12 weeks | 39 |
| Consumption of a soy drink has no effect on cognitive function but may alleviate vasomotor symptoms in post-menopausal women; a randomised trial 2020 · Medium-dose group · Apparently healthy post-menopausal women, within 1–7 years since their last menstrual period | 35 mg | 12 weeks | 38 |
| Consumption of a soy drink has no effect on cognitive function but may alleviate vasomotor symptoms in post-menopausal women; a randomised trial 2020 · High-dose group · Apparently healthy post-menopausal women, within 1–7 years since their last menstrual period | 60 mg | 12 weeks | 38 |
| Effects of Fermented Soy on Cognition in Older Adults: Outcomes of a Randomized, Controlled Trial 2025 · fermented soy · Healthy ambulatory men and postmenopausal women aged 65 years and older | 36.3 mg | 12 weeks | 33 |
| Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease 2015 · soy isoflavone group · men and postmenopausal women over age 60 with Alzheimer’s disease | 100 mg | 26 weeks | 32 |
| Soy germ isoflavones improve menopausal symptoms but have no effect on blood lipids in early postmenopausal Chinese women: a randomized placebo-controlled trial 2012 · 84 mg soy germ isoflavones · Chinese women aged 45–60 years in early postmenopause | 84 mg | 24 weeks | 30 |
| Soy germ isoflavones improve menopausal symptoms but have no effect on blood lipids in early postmenopausal Chinese women: a randomized placebo-controlled trial 2012 · 126 mg soy germ isoflavones · Chinese women aged 45–60 years in early postmenopause | 126 mg | 24 weeks | 30 |
| Supplementation of soy isoflavones improved sex hormones, blood pressure, and postmenopausal symptoms 2015 · experimental group · Postmenopausal women | 54 mg | 8 weeks | 30 |
| Polyunsaturated fatty acids (PUFAs) might reduce hot flushes: an indication from two controlled trials on soy isoflavones alone and with a PUFA supplement 2005 · Study A: soy isoflavone extract · Postmenopausal women with more than five troublesome hot flushes per day | 60 mg | 12 weeks | 29 |
| Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study 2003 · active treatment · Postmenopausal women aged 55–74 in good health, postmenopausal for at least 2 years, and not using estrogen replacement therapy | 110 mg | 26 weeks | 27 |
| Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy 2004 · soy germ isoflavones · Postmenopausal women with hot flushes and contraindications for conventional hormone replacement therapy | 60 mg | 26 weeks | 25 |
| Effect of soy isoflavone protein and soy lecithin on endothelial function in healthy postmenopausal women 2007 · soy isoflavone protein and placebo lecithin · Healthy postmenopausal women, mean age 61 years | 25 g | 4 weeks | 25 |
| Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease 2016 · Soy isoflavones and placebo of vitamin D (S+P) · Women aged 18–75 with irritable bowel syndrome (IBS) | 20 mg | 6 weeks | 25 |
| Isoflavone-rich soy protein prevents loss of hip lean mass but does not prevent the shift in regional fat distribution in perimenopausal women 2003 · SPI+ · Perimenopausal women; age range and specific conditions not stated | 40 g | 24 weeks | 24 |
| Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome 2005 · ISP containing soy isoflavones · Women aged 18–35 years with prospectively confirmed premenstrual syndrome and BMI 19–30 kg/m² | 68 mg | — | 23 |
| A meal enriched with soy isoflavones increases nitric oxide-mediated vasodilation in healthy postmenopausal women 2008 · isoflavone-enriched meal (ISO) · Healthy postmenopausal women | 80 mg | 1 day | 22 |
| Oral intake of soy isoflavone aglycone improves the aged skin of adult women 2007 · test food group · Women in their late 30s and early 40s with aged skin | 40 mg | 12 weeks | 13 |
| Genistein Supplementation and Cardiac Function in Postmenopausal Women with Metabolic Syndrome: Results from a Pilot Strain-Echo Study 2017 · genistein group · Postmenopausal women with type 2 diabetes and metabolic syndrome; age 55 years (median reported) | 54 mg | 1 year | 11 |
| Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study 2000 · soy isoflavone extract · Postmenopausal women, mean age 55 years, experiencing five or more hot flushes per day | 50 mg | 12 weeks | — |
| Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study 2002 · soy isoflavone extract group · Menopausal women in natural or surgical menopause with at least seven hot flushes per day; age not stated | 70 mg | 120 days | — |
| Isoflavones improve vascular reactivity in post-menopausal women with hypercholesterolemia 2004 · isoflavone group · post-menopausal women with hypercholesterolemia who were not taking estrogen replacement therapy | 90 mg | 6 weeks | — |
| Effects of soy isoflavones on menopausal neurovegetative symptoms 2004 · group A · postmenopausal women | 50 mg | 90 days | — |
| Effects of soy isoflavones on menopausal neurovegetative symptoms 2004 · group B · postmenopausal women | 75 mg | 90 days | — |
| Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function 2005 · soy supplement group · Postmenopausal women aged 51–66 years not taking other forms of hormone therapy | 60 mg | 6 weeks | — |
| Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones 2008 · equol-producing (EP) group · Healthy menopausal women who produced equol | 135 mg | 26 weeks | — |
| Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones 2008 · non-equol-producing (non-EP) group · Healthy menopausal women who did not produce equol | 135 mg | 26 weeks | — |
| Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms 2009 · isoflavones arm · Women aged 40–65 years with at least five moderate-to-severe hot flushes in the prior 7 days and no menstruation for at least 6 months | 80 mg | 12 weeks | — |
| [Effect of soy isoflavones on peri-menopausal symptom and estrogen] 2010 · SI group · Women with peri-menopausal symptoms; age not stated | 120 mg | 8 weeks | — |
| The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial 2010 · dietary soy supplementation · Healthy, symptomatic postmenopausal women aged 40–60 years | 90 mg | 16 weeks | — |
| Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial 2012 · intervention · men with benign prostate hyperplasia (BPH) and lower urinary tract symptoms | 40 mg | 1 year | — |
| Effects of standardized phytoestrogen on Taiwanese menopausal women 2012 · 35 mg soy extract group · Healthy Taiwanese postmenopausal women after natural menopause | 35 mg | 24 weeks | — |
| Effects of standardized phytoestrogen on Taiwanese menopausal women 2012 · 70 mg soy extract group · Healthy Taiwanese postmenopausal women after natural menopause | 70 mg | 24 weeks | — |
| Effects of a soy-based dietary supplement compared with low-dose hormone therapy on the urogenital system: a randomized, double-blind, controlled clinical trial 2015 · soy dietary supplement group · Healthy postmenopausal women aged 40 to 60 years | 90 mg | 16 weeks | — |
| Acupuncture or phy(F)itoestrogens vs. (E)strogen plus progestin on menopausal symptoms. A randomized study 2019 · soy isoflavones · postmenopausal women with hot flushes | 150 mg | 90 days | — |
| Soy isoflavones decrease fibroglandular breast tissue measured by magnetic resonance imaging in premenopausal women: A 2-year randomized double-blind placebo controlled clinical trial 2022 · isoflavone group · Healthy premenopausal women aged 30–42 years with monthly menstrual cycles | 137 mg | 2 years | 99 |
| Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial 2016 · ViveSoy® phase · Peri- or postmenopausal women aged 45 years or older with climacteric symptoms | 50 mg | 12 weeks | 90 |
| Nonhormonal management of postmenopausal women: effects of a red clover based isoflavones supplementation on climacteric syndrome and cardiovascular risk serum profile 2013 · phytoestrogens tablets · healthy postmenopausal women | 19.2 mg | 26 weeks | 75 |
| Soy protein supplementation in men following radical prostatectomy: a 2-year randomized, placebo-controlled clinical trial 2021 · soy · Men aged 44–75 at risk of cancer recurrence following radical prostatectomy | 41 mg | 2 years | 50 |
| Polyunsaturated fatty acids (PUFAs) might reduce hot flushes: an indication from two controlled trials on soy isoflavones alone and with a PUFA supplement 2005 · Study B: soy isoflavone extract with PUFA supplement · Postmenopausal women with more than five troublesome hot flushes per day | 60 mg | 12 weeks | 28 |
| Effect of soy isoflavone protein and soy lecithin on endothelial function in healthy postmenopausal women 2007 · soy isoflavone protein and soy lecithin · Healthy postmenopausal women, mean age 61 years | 25 g | 4 weeks | 25 |
| Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease 2016 · Soy isoflavones and vitamin D (S+D) · Women aged 18–75 with irritable bowel syndrome (IBS) | 20 mg | 6 weeks | 25 |
| Longer-term soy nut consumption improves vascular function and cardiometabolic risk markers in older adults: Results of a randomized, controlled cross-over trial 2022 · soy nut intervention · Healthy men and women aged 60–70 years with BMI 20–30 kg/m² | 174 mg | 16 weeks | 23 |
| Soy Protein Containing Isoflavones Improves Facial Signs of Photoaging and Skin Hydration in Postmenopausal Women: Results of a Prospective Randomized Double-Blind Controlled Trial 2023 · SPII (soy protein containing isoflavones) · Healthy postmenopausal women aged 50–70 with Fitzpatrick skin types I–III | 50 mg | 24 weeks | 23 |
| Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects 2014 · E+R+S · Healthy overweight women and men, mean age 35 years | 80 mg | 3 days | 18 |
| Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial 2010 · soy supplement · Postmenopausal women aged 45–60 with obesity (BMI 30–40 kg/m²), without diabetes; Caucasian and African American participants | 160 mg | 90 days | 17 |
| Influence of a new botanical combination on quality of life in menopausal Spanish women: Results of a randomized, placebo-controlled pilot study 2021 · Herbal extract · Healthy Spanish women aged 45–55 with menopause onset no more than five years earlier and initial Cervantes Scale score ≥53 | 200 mg | 8 weeks | 17 |
| Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women 2007 · Soy shake · Postmenopausal women aged 55.6 ± 1.4 years with BMI 30.5 ± 0.8 kg/m² and no diabetes | 160 mg | 90 days | 9 |
| Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine 2002 · phytoestrogen preparation · Women with menstrually associated migraine | 60 mg | 24 weeks | — |
| Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women 2003 · Isolated soy protein with isoflavones · Healthy postmenopausal women | 107 mg | 6 weeks | — |
| Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women 2003 · Ethanol-washed isolated soy protein with trace isoflavones · Healthy postmenopausal women | 2 mg | 6 weeks | — |
| The association between soy nut consumption and decreased menopausal symptoms 2007 · TLC diet plus soy nuts · Healthy postmenopausal women | 101 mg | 8 weeks | — |
| A mild favorable effect of soy protein with isoflavones on body composition--a 6-month double-blind randomized placebo-controlled trial among Chinese postmenopausal women 2010 · Soy group · Chinese postmenopausal women with mild hyperglycemia; age range not reported | 100 mg | 26 weeks | — |
| Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial 2012 · mixed soy isoflavones · Women aged 25–55 at increased risk for breast cancer or with a history of unilateral minimal-risk breast cancer; healthy, non-pregnant and non-lactating | 235 mg | 26 weeks | — |
| Long-term soy isoflavone supplementation and cognition in women: a randomized, controlled trial 2012 · isoflavone group · Healthy postmenopausal women aged 45–92 years | 91 mg | 913 days | — |
| Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study 2017 · equol and resveratrol group · Healthy recently menopausal women aged 50–55 years with hot flashes, anxiety and depressive symptoms | 210 mg | 12 weeks | — |
| Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial 2011 · ISP · Postmenopausal women without pre-existing cardiovascular disease; age range not specified | 25 g | 3 years | 175 |
| Daidzein and genistein have differential effects in decreasing whole body bone mineral density but had no effect on hip and spine density in premenopausal women: A 2-year randomized, double-blind, placebo-controlled study 2019 · isoflavone group · Healthy premenopausal women aged 30–42 years with regular monthly menstrual cycles | 137 mg | 2 years | 99 |
| Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women 2004 · ISO group · Healthy Japanese pre- and postmenopausal women | 100 mg | 24 weeks | 34 |
| Soy isoflavones attenuate bone loss in early postmenopausal Chinese women : a single-blind randomized, placebo-controlled trial 2006 · 84 mg isoflavones group · Chinese women aged 45–60 years in early postmenopause; non-obese, with high Kuppermann Scale | 84 mg | 26 weeks | 30 |
| Soy isoflavones attenuate bone loss in early postmenopausal Chinese women : a single-blind randomized, placebo-controlled trial 2006 · 126 mg isoflavones group · Chinese women aged 45–60 years in early postmenopause; non-obese, with high Kuppermann Scale | 126 mg | 26 weeks | 30 |
| Soy protein reduces serum LDL cholesterol and the LDL cholesterol:HDL cholesterol and apolipoprotein B:apolipoprotein A-I ratios in adults with type 2 diabetes 2009 · soy protein isolate (SPI) · Adults with diet-controlled type 2 diabetes | 80 mg | 57 days | 29 |
| A Non-Probiotic Fermented Soy Product Reduces Total and LDL Cholesterol: A Randomized Controlled Crossover Trial 2021 · fermented soy powder · Adult men and women aged 30–75 years with at least two cardiovascular disease risk factors | 25 g | 12 weeks | 27 |
| Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial 2004 · soy+ · Postmenopausal Caucasian women with established osteoporosis or at least 3 risk factors for osteoporosis | 76 mg | 2 years | 23 |
| Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial 2004 · combination of soy+ and TDP+ · Postmenopausal Caucasian women with established osteoporosis or at least 3 risk factors for osteoporosis | 76 mg | 2 years | 22 |
| Blood pressure and cardiovascular risk factors in women treated for climacteric symptoms with acupuncture, phytoestrogens, or hormones 2020 · phytoestrogens · Women reporting climacteric symptoms | 150 mg | 90 days | 22 |
| Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women 2001 · control · Postmenopausal women with normocholesterolemia or mild hypercholesterolemia | 7.1 mg | 93 days | 18 |
| Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women 2001 · low isoflavone · Postmenopausal women with normocholesterolemia or mild hypercholesterolemia | 65 mg | 93 days | 18 |
| Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women 2001 · high isoflavone · Postmenopausal women with normocholesterolemia or mild hypercholesterolemia | 132 mg | 93 days | 18 |
| Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women 2000 · control · Healthy, normocholesterolemic, premenopausal women | 10 mg | — | — |
| Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women 2000 · low-isoflavone intake · Healthy, normocholesterolemic, premenopausal women | 64.7 mg | — | — |
| Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women 2000 · high-isoflavone intake · Healthy, normocholesterolemic, premenopausal women | 129 mg | — | — |
| Soy protein and bone mineral density in older men and women: a randomized trial 2006 · +ISO · Men and women aged 50–80 years | 83 mg | 1 year | — |
| Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial 2007 · isoflavone group · Early postmenopausal Japanese women, classified by equol-producer phenotype | 75 mg | 1 year | — |
| Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods 2012 · Soy foods with high-normal isoflavones · Hypercholesterolemic men and postmenopausal women | 73 mg | 30 days | — |
| Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods 2012 · Soy foods with low isoflavones · Hypercholesterolemic men and postmenopausal women | 10 mg | 30 days | — |
| Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial 2013 · control protein + isoflavone tablets (CPI) · Postmenopausal women; mean age not stated; generally healthy, late postmenopausal women | 105 mg | 1 year | — |
| Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: a 6-month randomized, double-blind, and placebo-controlled trial in equol-producing postmenopausal women 2014 · daidzein group · Prehypertensive postmenopausal women who were equol producers | 63 mg | 26 weeks | — |
| Wrinkle reduction in post-menopausal women consuming a novel oral supplement: a double-blind placebo-controlled randomized study 2014 · Test group 1 · Healthy, non-smoking post-menopausal women, skin types I–III, not receiving HRT and with BMI 18–33 kg/m² | 70 mg | 14 weeks | 55 |
| Wrinkle reduction in post-menopausal women consuming a novel oral supplement: a double-blind placebo-controlled randomized study 2014 · Test group 2 · Healthy, non-smoking post-menopausal women, skin types I–III, not receiving HRT and with BMI 18–33 kg/m² | 40 mg | 14 weeks | 55 |
| Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause 2006 · ES (Estromineral serena) · Symptomatic menopausal women with sleep or mood alterations | 60 mg | 24 weeks | 44 |
| The soy isoflavones for reducing bone loss study: 3-yr effects on pQCT bone mineral density and strength measures in postmenopausal women 2011 · 80 mg of isoflavones · Postmenopausal women aged 46.1–63.1 years, 0.8–7.88 years since last menstrual period, without diagnosed chronic disease | 80 mg | 3 years | — |
| The soy isoflavones for reducing bone loss study: 3-yr effects on pQCT bone mineral density and strength measures in postmenopausal women 2011 · 120 mg of isoflavones · Postmenopausal women aged 46.1–63.1 years, 0.8–7.88 years since last menstrual period, without diagnosed chronic disease | 120 mg | 3 years | — |
| Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial 2007 · genistein · Postmenopausal women with osteopenia and femoral-neck BMD below 0.795 g/cm2 | 54 mg | 2 years | 198 |
| Effect of exercise training combined with isoflavone supplementation on bone and lipids in postmenopausal women: a randomized clinical trial 2013 · Isoflavone supplementation (Iso) · Postmenopausal women; age and other conditions not specified | 165 mg | 2 years | 90 |
| Effect of exercise training combined with isoflavone supplementation on bone and lipids in postmenopausal women: a randomized clinical trial 2013 · Combined exercise and isoflavone (ExIso) · Postmenopausal women; age and other conditions not specified | 165 mg | 2 years | 87 |
| Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women 2007 · TLC diet plus soy nuts · Healthy postmenopausal women, including hypertensive, prehypertensive, and normotensive women | 101 mg | 8 weeks | 60 |
| Effect of soy nuts and equol status on blood pressure, lipids and inflammation in postmenopausal women stratified by metabolic syndrome status 2015 · TLC diet with soy nuts · Healthy postmenopausal women, with and without metabolic syndrome; no atherosclerosis or diabetes | 101 mg | 8 weeks | 60 |
| Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial 2023 · equol/resveratrol combination · Caucasian postmenopausal women aged 50–55 with menopausal complaints and BMI 20 to <25 kg/m² | 80 mg | 1 year | 38 |
| Effect of soy protein varying in isoflavone content on serum lipids in healthy young men 2006 · low-isoflavone soy protein isolate (low-iso SPI) · Healthy young men; mean age 27.9 ± 5.7 years | 1.64 mg | 57 days | 35 |
| Effect of soy protein varying in isoflavone content on serum lipids in healthy young men 2006 · high-isoflavone SPI (high-iso SPI) · Healthy young men; mean age 27.9 ± 5.7 years | 61.7 mg | 57 days | 35 |
| The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women 2001 · Soy+ group · Postmenopausal women with moderate hypercholesterolemia | 80 mg | 12 weeks | 31 |
| [Relationship between estrogen receptor gene Px haplotype and the effect of calcium and soy isoflavone supplementation on bone mineral density of Chinese postmenopausal women] 2008 · Ca + soy isoflavone group · Chinese postmenopausal women aged 45–65 with baseline BMD T score < -1.5 | 100 mg | 1 year | 26 |
| Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women 2000 · SPI+ (isoflavone-rich soy) · Perimenopausal women | 80.4 mg | 24 weeks | 24 |
| Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects 2001 · Abalon · Adults with type 2 diabetes | 165 mg | 6 weeks | — |
| Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women 2001 · soy protein isolate group · Healthy men and postmenopausal women aged 50–75 years | 118 mg | 90 days | — |
| Effects of soy supplementation on blood lipids and arterial function in hypercholesterolaemic subjects 2005 · soy supplement (Abalon) · Hypercholesterolaemic but otherwise healthy adults; age range and sex not stated | 100 mg | 24 weeks | — |
| [The effects of phytoestrogen on blood pressure and lipids in healthy volunteers] 2006 · soy protein isolate group · Healthy men and post-menopausal women aged 50–76 years | 118 mg | 90 days | — |
| Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial 2009 · 80 mg soy isoflavones group · Postmenopausal women; described as healthy | 80 mg | 2 years | — |
| Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial 2009 · 120 mg soy isoflavones group · Postmenopausal women; described as healthy | 120 mg | 2 years | — |
| The effect on the blood lipid profile of soy foods combined with a prebiotic: a randomized controlled trial 2010 · soy food-containing diet · Hyperlipidemic adults; mean age 58 ± 7 years; 11 men and 12 women | 61 mg | 4 weeks | — |
| The effect on the blood lipid profile of soy foods combined with a prebiotic: a randomized controlled trial 2010 · soy food-containing diet with prebiotic · Hyperlipidemic adults; mean age 58 ± 7 years; 11 men and 12 women | 61 mg | 4 weeks | — |
| Effect of soy protein and isoflavones on blood pressure and endothelial cytokines: a 6-month randomized controlled trial among postmenopausal women 2013 · Soy group · Postmenopausal Chinese women with mild hyperglycemia; subgroup analysis included women with prehypertension or hypertension | 100 mg | 26 weeks | — |
| Effect of soy protein and isoflavones on blood pressure and endothelial cytokines: a 6-month randomized controlled trial among postmenopausal women 2013 · Iso group · Postmenopausal Chinese women with mild hyperglycemia | 100 mg | 26 weeks | — |
| Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial 2013 · soy protein + isoflavone tablets (SPI) · Postmenopausal women; mean age not stated; generally healthy, late postmenopausal women | 105 mg | 1 year | — |
| Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause 2018 · soy protein with isoflavones (SPI) · Women in the early menopause, mean age 55 years | 66 mg | 26 weeks | — |
| Soy isoflavones interact with calcium and contribute to blood pressure homeostasis in women: a randomized, double-blind, placebo controlled trial 2020 · Isoflavone group · Healthy premenopausal women aged 30–42 years | 137 mg | 2 years | — |
| Food matrix and isoflavones bioavailability in early post menopausal women: a European clinical study 2008 · IF-enriched biscuits · Healthy postmenopausal women aged 49–60 years | 100 mg | 3 days | 42 |
| Food matrix and isoflavones bioavailability in early post menopausal women: a European clinical study 2008 · IF-enriched cereal bars · Healthy postmenopausal women aged 49–60 years | 100 mg | 3 days | 42 |
| Mothers' Consumption of Soy Drink But Not Black Tea Increases the Flavonoid Content of Term Breast Milk: A Pilot Randomized, Controlled Intervention Study 2017 · soy drink · Healthy nursing women | 12 mg | 6 days | 18 |
| Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation 2009 · isoflavone group · Men with newly diagnosed, clinically localized prostate cancer undergoing radical prostatectomy | 82 mg | 2 weeks | 14 |
| Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal japanese women: a four-week study 2002 · isoflavone group · Healthy perimenopausal women | 61.8 mg | 4 weeks | 12 |
| Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women 2005 · Soy beverage · Postmenopausal Thai women aged 46–61 years in good health | 15 g | 1 day | 12 |
| Higher bioavailability of isoflavones after a single ingestion of a soya-based supplement than a soya-based food in young healthy males 2008 · soya-based supplement · Young healthy males | 35 mg | 1 day | 12 |
| Orally administered isoflavones are present as glucuronides in the human prostate 2008 · soy extract supplementation · Men with benign prostatic hyperplasia undergoing prostate surgery; age not reported | 113 mg | 3 days | 12 |
| Effects of isoflavone supplements vs. soy foods on blood concentrations of genistein and daidzein in adults 2009 · one Novasoy tablet three times/day · Generally healthy adults aged 28–74; five postmenopausal women, four premenopausal women, and four men enrolled | 144 mg | 7 days | 12 |
| Effects of isoflavone supplements vs. soy foods on blood concentrations of genistein and daidzein in adults 2009 · two Novasoy tablets three times/day · Generally healthy adults aged 28–74; five postmenopausal women, four premenopausal women, and four men enrolled | 144 mg | 7 days | 12 |
| Influence of ethnic origin (Asian v. Caucasian) and background diet on the bioavailability of dietary isoflavones 2009 · Asian participants under the Western diet · Healthy young Asian adults; non-equol producers | 46 mg | 10 days | 12 |
| Influence of ethnic origin (Asian v. Caucasian) and background diet on the bioavailability of dietary isoflavones 2009 · Asian participants under the Asian diet · Healthy young Asian adults; non-equol producers | 46 mg | 10 days | 12 |
| Influence of ethnic origin (Asian v. Caucasian) and background diet on the bioavailability of dietary isoflavones 2009 · Caucasian participants under the Western diet · Healthy young male Caucasian adults; non-equol producers | 46 mg | 10 days | 12 |
| Plasma phytoestrogens are not altered by probiotic consumption in postmenopausal women with and without a history of breast cancer 2004 · soy protein (S) · Postmenopausal women, including breast cancer survivors and controls | 26.6 g | 6 weeks | — |
| Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults 2004 · high-soy diet · Healthy young adults; age range and sex breakdown not reported | 104 mg | 10 weeks | — |
| Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults 2004 · low-soy diet · Healthy young adults; age range and sex breakdown not reported | 540 mcg | 10 weeks | — |
| Bioavailability of isoflavone phytoestrogens in postmenopausal women consuming soya milk fermented with probiotic bifidobacteria 2005 · Non-fermented soya milk, 80 mg isoflavone/200 ml · Postmenopausal women | 240 mg | 2 weeks | — |
| Urinary estrogen metabolites during a randomized soy trial 2012 · high-soy diet · Non-lactating premenopausal women of diverse ethnicities; no diagnosed condition stated | 50 mg | 26 weeks | 82 |
| Effect of soy nuts on adhesion molecules and markers of inflammation in hypertensive and normotensive postmenopausal women 2008 · TLC diet with soy nuts replacing non-soy protein · Postmenopausal women, mean ages 53.5 years (normotensive) and 58.3 years (hypertensive); healthy and without clinical atherosclerosis or diabetes | 101 mg | 8 weeks | 60 |
| Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial 2013 · soy isoflavone · Men with localized prostate cancer, clinical stage T1 or T2, scheduled to undergo prostatectomy | 51 mg | 6 weeks | 42 |
| Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer 2010 · GCP group · Men with histologically confirmed low-volume prostate cancer on active surveillance, with rising PSA and no prior prostate cancer treatment | 5 g | 1 year | 36 |
| The Effects of Soy Isoflavones on Metabolic Status of Patients With Polycystic Ovary Syndrome 2016 · soy isoflavones · Women aged 18–40 with polycystic ovary syndrome diagnosed according to the Rotterdam criteria | 50 mg | 12 weeks | 35 |
| Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women 2006 · Isoflavones · Healthy postmenopausal women; age 59 ± 6 years | 50 mg | 8 weeks | 34 |
| Marked individual variation in isoflavone metabolism after a soy challenge can modulate the skeletal effect of isoflavones in premenopausal women 2009 · soy group · Healthy premenopausal Korean women aged 30–50 years | 120 mg | 12 weeks | 32 |
| Seaweed and soy: companion foods in Asian cuisine and their effects on thyroid function in American women 2007 · Soy protein isolate during placebo treatment period · Healthy postmenopausal women, mean age 58 years | 2 mg/kg | 7 days | 25 |
| The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A 2024 · soy isoflavone group · Adults with non-alcoholic fatty liver disease and grade 2 or higher steatosis; men and women, age 18 or older | 100 mg | 12 weeks | 25 |
| The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial 2024 · soy isoflavone group · Adults aged 18 years or older with grade 2 or higher non-alcoholic fatty liver disease; men and women | 100 mg | 12 weeks | 25 |
| Soy isoflavones improve bone metabolism in postmenopausal Japanese women 2004 · ISO · Women; a subgroup of the study participants was postmenopausal | 40 mg | 4 weeks | 24 |
| Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial 2011 · genistein · Patients with localized prostate cancer | 30 mg | 6 weeks | 23 |
| Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects 2002 · high-isoflavone diet · Young, healthy, normolipidemic adults; 5 men and 17 women | 56 mg | 17 days | 22 |
| Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects 2002 · low-isoflavone diet · Young, healthy, normolipidemic adults; 5 men and 17 women | 2 mg | 17 days | 22 |
| Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: a ten-week study 2002 · isoflavone-administered group · Healthy postmenopausal Japanese immigrant women living in Brazil | 37.3 mg | 10 weeks | 20 |
| Soy food supplementation, dietary fat reduction and peripheral blood gene expression in postmenopausal women--a randomized, controlled trial 2011 · SFD group · Healthy postmenopausal women | 50 mg | 8 weeks | 20 |
| Decreased bone resorption with soy isoflavone supplementation in postmenopausal women 2004 · soy isoflavone supplementation · Postmenopausal women; mean age 70.6 years | 110 mg | 26 weeks | 19 |
| Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women 2009 · high dose · Premenopausal women aged 19–54 without a history of breast cancer | 129 mg | — | 19 |
| Modest hormonal effects of soy isoflavones in postmenopausal women 1999 · control · postmenopausal women | 0.11 mg/kg | 93 days | 18 |
| Modest hormonal effects of soy isoflavones in postmenopausal women 1999 · low-iso · postmenopausal women | 1 mg/kg | 93 days | 18 |
| Modest hormonal effects of soy isoflavones in postmenopausal women 1999 · high-iso · postmenopausal women | 2 mg/kg | 93 days | 18 |
| Soy consumption alters endogenous estrogen metabolism in postmenopausal women 2000 · 0.1 mg isoflavones/kg body weight/day control diet · Healthy postmenopausal women | 0.1 mg/kg | 93 days | 18 |
| Soy consumption alters endogenous estrogen metabolism in postmenopausal women 2000 · 1 mg isoflavones/kg body weight/day diet · Healthy postmenopausal women | 1 mg/kg | 93 days | 18 |
| Soy consumption alters endogenous estrogen metabolism in postmenopausal women 2000 · 2 mg isoflavones/kg body weight/day diet · Healthy postmenopausal women | 2 mg/kg | 93 days | 18 |
| Effects of a high daily dose of soy isoflavones on DNA damage, apoptosis, and estrogenic outcomes in healthy postmenopausal women: a phase I clinical trial 2008 · Active group · Healthy, non-obese postmenopausal women; mean age 56.8 years in the active group | 600 mg | 12 weeks | 18 |
| Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer 2010 · Placebo-to-GCP open-label group · Men with histologically confirmed low-volume prostate cancer on active surveillance who had been assigned to placebo in the randomized phase and were eligible for the extension | 5 g | 26 weeks | 18 |
| Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women 2006 · isoflavone supplement · healthy postmenopausal women | 100 mg | 12 weeks | 15 |
| Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women 2009 · low dose · Premenopausal women aged 19–54 without a history of breast cancer | 37.2 mg | — | 15 |
| Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial 2022 · genistein · Adults aged 54–75 with prodromal Alzheimer’s disease and amyloid-positive mild cognitive impairment | 120 mg | 360 days | 14 |
| Soy isoflavones exert modest hormonal effects in premenopausal women 1999 · control diet · 14 premenopausal women | 10 mg | — | 14 |
| Soy isoflavones exert modest hormonal effects in premenopausal women 1999 · low isoflavone diet · 14 premenopausal women | 64 mg | — | 14 |
| Soy isoflavones exert modest hormonal effects in premenopausal women 1999 · high isoflavone diet · 14 premenopausal women | 128 mg | — | 14 |
| Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women 1998 · Control diet (0.16 mg/kg/day) · Healthy premenopausal women | 0.16 mg/kg | 100 days | 12 |
| Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women 1998 · 1.01 mg/kg/day isoflavone diet · Healthy premenopausal women | 1.01 mg/kg | 100 days | 12 |
| Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women 1998 · 2.01 mg/kg/day isoflavone diet · Healthy premenopausal women | 2.01 mg/kg | 100 days | 12 |
| The specific role of isoflavones on estrogen metabolism in premenopausal women 2002 · experimental group · Healthy premenopausal women aged 25–55 years, without breast carcinoma | 40 mg | 12 weeks | — |
| Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women 2002 · high-isoflavone soyfood diet · Men and postmenopausal women with hyperlipidemia | 73 mg | 30 days | — |
| Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women 2002 · low-isoflavone soyfood diet · Men and postmenopausal women with hyperlipidemia | 10 mg | 30 days | — |
| Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers 2005 · 30 mg group · healthy volunteers; age and sex not specified | 30 mg | 1 day | — |
| Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers 2005 · 60 mg group · healthy volunteers; age and sex not specified | 60 mg | 1 day | — |
| Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers 2005 · 150 mg group · healthy volunteers; age and sex not specified | 150 mg | 1 day | — |
| Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers 2005 · 300 mg group · healthy volunteers; age and sex not specified | 300 mg | 1 day | — |
| Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production 2005 · isoflavone · Healthy European postmenopausal women | 50 mg | 8 weeks | — |
| Soy isoflavones modulate immune function in healthy postmenopausal women 2006 · supplement · Postmenopausal women aged 50–65 years | 70 mg | 16 weeks | — |
| Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk 2007 · soy germ pasta · Adults with hypercholesterolemia | 33 mg | 8 weeks | — |
| Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients 2009 · soy isoflavone supplement (Novasoy) · Men with newly diagnosed, clinically localized prostate adenocarcinoma scheduled for prostatectomy; age not stated | 81.6 mg | 2 weeks | — |
| Soy isoflavones, Mediterranean diet, and physical exercise in postmenopausal women with insulin resistance 2010 · soy isoflavones group · Postmenopausal women with insulin resistance | 40 mg | 2 years | — |
| Soy isoflavones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women 2011 · soy isoflavones group · Obese postmenopausal women described as healthy | 80 mg | 26 weeks | — |
| Serum IGF-1 concentrations change with soy and seaweed supplements in healthy postmenopausal American women 2011 · soy · Healthy postmenopausal European-American women, mean age 58.4 years; some were breast cancer survivors without current disease | 100 g | 7 days | — |
| Isoflavone supplementation influenced levels of triglyceride and luteunizing hormone in Korean postmenopausal women 2013 · isoflavone group · Korean postmenopausal women with FSH levels higher than 40 IU/ml | 70 mg | 12 weeks | — |
| Effect of whole soy and purified isoflavone daidzein on renal function--a 6-month randomized controlled trial in equol-producing postmenopausal women with prehypertension 2014 · daidzein group · Chinese postmenopausal women with prehypertension who were equol producers | 63 mg | 26 weeks | — |
| Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial 2015 · Genistein-rich soy supplement, 52.85 mg/d · Postmenopausal women prescreened for ability to convert daidzein to equol | 52.9 mg | 50 days | — |
| Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial 2015 · Genistein-rich soy supplement, 113.52 mg/d · Postmenopausal women prescreened for ability to convert daidzein to equol | 114 mg | 50 days | — |
| Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial 2015 · Mixed soy isoflavones in natural ratios, 105.23 mg/d · Postmenopausal women prescreened for ability to convert daidzein to equol | 105 mg | 50 days | — |
| Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells 2015 · soy bread · Men with prostate cancer and asymptomatic biochemical recurrence; age range not reported | 68 mg | 8 weeks | — |
| Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells 2015 · soy-almond bread · Men with prostate cancer and asymptomatic biochemical recurrence; age range not reported | 68 mg | 8 weeks | — |
| Effect of whole soy and purified daidzein on androgenic hormones in chinese equol-producing post-menopausal women: a six-month randomised, double-blinded and Placebo-Controlled trial 2020 · daidzein group · Chinese equol-producing post-menopausal women aged 45–70 years | 63 mg | 26 weeks | — |
| Effects of soy isoflavones on serum systemic and vascular inflammation markers and oxidative stress in peritoneal dialysis patients: A randomized controlled trial 2020 · isoflavone group · Peritoneal dialysis patients; age and sex not specified | 100 mg | 8 weeks | — |
| Effects of isoflavones on bone turnover markers in peritoneal dialysis patients: a randomized controlled trial 2020 · soy isoflavone group · Peritoneal dialysis patients; age and sex not specified | 100 mg | 8 weeks | — |
| Effects of soy isoflavones on serum lipids and lipoprotein (a) in peritoneal dialysis patients 2020 · isoflavone group · Peritoneal dialysis patients; age and sex not reported | 100 mg | 8 weeks | — |
| Effects of Soy Isoflavones on Glycemic Parameters and Blood Pressure in Peritoneal Dialysis Patients: A Randomized, Double Blind, Placebo-Controlled Trial 2021 · isoflavone group · Peritoneal dialysis patients; age and sex not specified | 100 mg | 8 weeks | — |
| Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast 1998 · Soy supplement group · Premenopausal women with benign or malignant breast disease and histologically normal breast epithelium | 45 mg | 2 weeks | — |
| Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast 1999 · Dietary soy supplementation · Premenopausal patients with normal breasts | 45 mg | 2 weeks | 84 |
| Large inter-individual variation in isoflavone plasma concentration limits use of isoflavone intake data for risk assessment 2014 · GD study GEN arm · Postmenopausal women, including equol producers and non-producers | 102 mg | 8 weeks | 35 |
| Large inter-individual variation in isoflavone plasma concentration limits use of isoflavone intake data for risk assessment 2014 · GD study DAI arm · Postmenopausal women who were equol producers | 56 mg | 8 weeks | 32 |
| Seaweed and soy: companion foods in Asian cuisine and their effects on thyroid function in American women 2007 · Seaweed treatment period with soy protein isolate · Healthy postmenopausal women, mean age 58 years | 2 mg/kg | 7 weeks | 25 |
| Large inter-individual variation in isoflavone plasma concentration limits use of isoflavone intake data for risk assessment 2014 · ISO study isoflavone supplement; also used in the GD study DAI arm · Postmenopausal women; all participants in the ISO study and participants in the DAI arm were equol producers | 56 mg | 8 weeks | 21 |
| Effect of Lactobacillus sporogenes on oral isoflavones bioavailability: single dose pharmacokinetic study in menopausal women 2011 · R (reference formulation) · Menopausal women, mean age 54.3 years, receiving antibiotic therapy | 60 mg | 1 day | 12 |
| Effect of Lactobacillus sporogenes on oral isoflavones bioavailability: single dose pharmacokinetic study in menopausal women 2011 · E (Estromineral test formulation) · Menopausal women, mean age 54.3 years, receiving antibiotic therapy | 60 mg | 1 day | 12 |
| Disposition of soy isoflavones in normal human breast tissue 2010 · soy milk · healthy women undergoing breast reduction | 50.9 mg | 5 days | 11 |
| Disposition of soy isoflavones in normal human breast tissue 2010 · soy supplement · healthy women undergoing breast reduction | 68.5 mg | 5 days | 10 |
| Effects of dietary intake of soy protein and isoflavones on cardiovascular disease risk factors in high risk, middle-aged men in Scotland 2004 · soy-containing diet group · Men aged 45 to 59 with relatively higher blood pressure and/or total cholesterol levels | 80 mg | 5 weeks | — |
| Plasma phytoestrogens are not altered by probiotic consumption in postmenopausal women with and without a history of breast cancer 2004 · soy + probiotics (S+P) · Postmenopausal women, including breast cancer survivors and controls | 26.6 g | 6 weeks | — |
| Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer 2015 · soy bread (SB) · Men aged 52–84 with asymptomatic prostate cancer after primary therapy or during active surveillance and rising PSA | 69.8 mg | 8 weeks | — |
| Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer 2015 · soy-almond bread (SAB) · Men aged 52–84 with asymptomatic prostate cancer after primary therapy or during active surveillance and rising PSA | 69.4 mg | 8 weeks | — |
| Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study 2007 · genistein group · Osteopenic, postmenopausal women; age range not reported | 54 mg | 2 years | 198 |
| Equol production changes over time in postmenopausal women 2012 · soy group · Postmenopausal women, predominantly Caucasian; no specific disease stated. | 90 mg | 913 days | 175 |
| Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - a randomised controlled study 2017 · SPI group · Men aged 45–75 with type 2 diabetes, low testosterone and normal FSH and LH | 66 mg | 90 days | 100 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · mid-dose · Postmenopausal Chinese women aged 48–62 years | 40 mg | 1 year | 68 |
| Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial 2003 · high dose · Postmenopausal Chinese women aged 48–62 years | 80 mg | 1 year | 68 |
| Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial 2004 · mid-dose · Postmenopausal Chinese women aged 48 to 62 years | 40 mg | 1 year | 68 |
| Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial 2004 · high-dose · Postmenopausal Chinese women aged 48 to 62 years | 80 mg | 1 year | 68 |
| Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: a double-blind, randomized, placebo-controlled trial 2007 · 40 mg isoflavones · Postmenopausal Chinese women aged 48 to 62 years | 40 mg | 1 year | 68 |
| Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: a double-blind, randomized, placebo-controlled trial 2007 · 80 mg isoflavones · Postmenopausal Chinese women aged 48 to 62 years | 80 mg | 1 year | 68 |
| Endometrial, breast and liver safety of soy isoflavones plus Lactobacillus sporogenes in post-menopausal women 2013 · group E · Healthy postmenopausal women with menopausal symptoms | 60 mg | 1 year | 65 |
| Soy-tibolone combination - effect on lipids in postmenopausal monkeys and women 2008 · soy powder · Postmenopausal women, mean age 57.7 years, with or without daidzein-to-equol conversion capability, treated with tibolone | 112 mg | 8 weeks | 40 |
| Soy protein isolates of varying isoflavone content exert minor effects on serum reproductive hormones in healthy young men 2005 · low-isoflavone soy protein isolate (low-iso SPI) · Healthy young men | 1.64 mg | 57 days | 35 |
| Soy protein isolates of varying isoflavone content exert minor effects on serum reproductive hormones in healthy young men 2005 · high-isoflavone soy protein isolate (high-iso SPI) · Healthy young men | 61.7 mg | 57 days | 35 |
| The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen 2001 · ISP+ · Elderly men with elevated serum prostate-specific antigen (PSA) | 69 mg | 6 weeks | 34 |
| The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen 2001 · ISP- · Elderly men with elevated serum prostate-specific antigen (PSA) | 3.4 mg | 6 weeks | 34 |
| Lycopene and soy isoflavones in the treatment of prostate cancer 2007 · lycopene plus soy isoflavones · Men with prostate cancer and rising serum PSA following local therapy or while on hormone therapy | 80 mg | 26 weeks | 33 |
| Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes 2002 · phytoestrogen supplementation · Postmenopausal women with diet-controlled type 2 diabetes | 132 mg | 12 weeks | 32 |
| Effects of high-dose isoflavones on metabolic and inflammatory markers in healthy postmenopausal women 2009 · soy protein / isoflavone group · Postmenopausal women, mean age 57 years, without diabetes or other specified excluded conditions | 160 mg | 12 weeks | 32 |
| Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity--a controlled crossover trial 2000 · Test diet · Adults with hyperlipidemia; age and sex not specified | 86 mg | 30 days | 31 |
| Effect of soy-based breakfast cereal on blood lipids and oxidized low-density lipoprotein 2000 · soy breakfast cereal · Hyperlipidemic men and women; ages and sex distribution not reported | 168 mg | 3 weeks | 25 |
| Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women 2005 · soy protein isolate · Healthy postmenopausal women aged 50–75 years | 118 mg | 90 days | 19 |
| Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women 1999 · 20 g soy protein containing 34 mg of phytoestrogens given in a single dose · Perimenopausal women; age range and specific conditions not stated | 34 mg | 6 weeks | — |
| Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women 1999 · 20 g of soy protein containing 34 mg of phytoestrogens split into two doses · Perimenopausal women; age range and specific conditions not stated | 34 mg | 6 weeks | — |
| A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins 1999 · soy protein containing 3 mg of isoflavones · Healthy men and women with mildly elevated LDL cholesterol, after instruction in a National Cholesterol Education Program Step I diet | 3 mg | 9 weeks | — |
| A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins 1999 · soy protein containing 27 mg of isoflavones · Healthy men and women with mildly elevated LDL cholesterol, after instruction in a National Cholesterol Education Program Step I diet | 27 mg | 9 weeks | — |
| A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins 1999 · soy protein containing 37 mg of isoflavones · Healthy men and women with mildly elevated LDL cholesterol, after instruction in a National Cholesterol Education Program Step I diet | 37 mg | 9 weeks | — |
| A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins 1999 · soy protein containing 62 mg of isoflavones · Healthy men and women with mildly elevated LDL cholesterol, after instruction in a National Cholesterol Education Program Step I diet | 62 mg | 9 weeks | — |
| Probiotic consumption does not enhance the cholesterol-lowering effect of soy in postmenopausal women 2004 · soy protein isolate · postmenopausal women | 44 mg | 6 weeks | — |
| Probiotic consumption does not enhance the cholesterol-lowering effect of soy in postmenopausal women 2004 · soy protein isolate + probiotic capsules · postmenopausal women | 44 mg | 6 weeks | — |
| The hypoglycemic effects of soy isoflavones on postmenopausal women 2004 · isoflavone group · Postmenopausal Taiwanese women | 100 mg | 26 weeks | — |
| The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption 2005 · soy protein · Postmenopausal women, including breast cancer survivors and controls | 44.4 mg | 6 weeks | — |
| Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer 2007 · SPI+ (soy protein isolate) · Men at high risk of developing advanced prostate cancer | 107 mg | 26 weeks | — |
| Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer 2007 · SPI- (alcohol-washed soy protein isolate) · Men at high risk of developing advanced prostate cancer | 6 mg | 26 weeks | — |
| Soy protein isolate increases urinary estrogens and the ratio of 2:16alpha-hydroxyestrone in men at high risk of prostate cancer 2007 · isoflavone-rich soy protein isolate (SPI+) · Men at high risk for developing advanced prostate cancer | 107 mg | 26 weeks | — |
| Soy protein isolate increases urinary estrogens and the ratio of 2:16alpha-hydroxyestrone in men at high risk of prostate cancer 2007 · alcohol-washed soy protein isolate (SPI-) · Men at high risk for developing advanced prostate cancer | 6 mg | 26 weeks | — |
| Effects of soy bean on serum paraoxonase 1 activity and lipoproteins in hyperlipidemic postmenopausal women 2009 · soy group · Hypercholesterolemic postmenopausal women | 164 mg | 10 weeks | — |
| Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women 2009 · Seaweed schedule, with soy challenge during week 7 · Healthy postmenopausal women | 2 mg/kg | 7 weeks | — |
| [Changes of serum lipids after soy isoflavone and calcium supplementation in postmenopausal Chinese women with different ER-beta genotypes] 2011 · group II · Postmenopausal Chinese women with normal serum lipids and bone loss or osteoporosis | 100 mg | 1 year | — |
| Serum IGF-1 concentrations change with soy and seaweed supplements in healthy postmenopausal American women 2011 · SeaSoy (combination of seaweed and soy) · Healthy postmenopausal European-American women, mean age 58.4 years; some were breast cancer survivors without current disease | 100 g | 7 days | — |
| A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients 2012 · G-2535, 300 mg genistein/day · Adults aged 46–97 with an initial or recurrent bladder tumor scheduled for TURBT or cystectomy | 450 mg | 30 days | — |
| A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients 2012 · G-2535, 600 mg genistein/day · Adults aged 46–97 with an initial or recurrent bladder tumor scheduled for TURBT or cystectomy | 900 mg | 30 days | — |
| Effect of soybean protein on novel cardiovascular disease risk factors: a randomized controlled trial 2013 · soy protein · Men and women aged 22 years or older with mean systolic blood pressure 120–159 mm Hg and diastolic blood pressure 80–95 mm Hg | 89.3 mg | 8 weeks | — |
| Effect of soy isoflavone supplementation on vascular endothelial function and oxidative stress in postmenopausal women: a community randomized controlled trial 2013 · intervention group · Indonesian postmenopausal women aged 47 to 60 years | 100 mg | 1 year | — |
| Effect of soy isoflavone supplementation on endothelial dysfunction and oxidative stress in equol-producing postmenopausal women 2015 · Intervention group · Postmenopausal Indonesian women aged 47–60 years, stratified by equol-producer status | 100 mg | 26 weeks | — |
| Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial 2017 · soy protein with isoflavone (SPI) · Women within 2 years after the onset of menopause | 66 mg | 26 weeks | — |
| Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism: A Randomized Controlled Study 2017 · Soy protein with isoflavones (SPI) · Men with type 2 diabetes mellitus and total testosterone ≤12 nmol/L | 66 mg | 90 days | — |
| Novel effects of phytoestrogenic soy isoflavones on serum calcium and chloride in premenopausal women: A 2-year double-blind, randomized, placebo-controlled study 2018 · isoflavone group · Premenopausal women aged 30–42 years with regular monthly menstrual cycles | 492 mg | 2 years | — |
| Evaluation of effect of isoflavone on thyroid economy & autoimmunity in oophorectomised women: a randomised, double-blind, placebo-controlled trial 2011 · isoflavone group · Women younger than 55 years with bilateral oophorectomy and normal baseline TSH | 75 mg | 12 weeks | 21 |
| Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women 2007 · SPI + EX · Postmenopausal women aged 50–65 years | 91.2 mg | 274 days | 11 |
| Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women 2007 · SPI · Postmenopausal women aged 50–65 years | 91.2 mg | 274 days | 10 |
| The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption 2005 · soy protein + probiotics · Postmenopausal women, including breast cancer survivors and controls | 44.4 mg | 6 weeks | — |
| A mild favorable effect of soy protein with isoflavones on body composition--a 6-month double-blind randomized placebo-controlled trial among Chinese postmenopausal women 2010 · Iso group · Chinese postmenopausal women with mild hyperglycemia; age range not reported | 100 mg | 26 weeks | — |
| Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: a 1-year investigation 2010 · low-dose soy isoflavones · Healthy postmenopausal women aged 45.8–65.0 years, selected as at risk because they were less than 10 years since their last menses | 80 mg | 3 years | — |
| Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: a 1-year investigation 2010 · high-dose soy isoflavones · Healthy postmenopausal women aged 45.8–65.0 years, selected as at risk because they were less than 10 years since their last menses | 120 mg | 3 years | — |